Eloralintide vs Retatrutide: Amylin vs Triple Agonist
Eloralintide vs retatrutide: two investigational Lilly obesity drugs on different pathways — amylin vs GIP/GLP-1/glucagon. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Both are investigational Eli Lilly obesity candidates. Retatrutide is a triple agonist (GIP, GLP-1 and glucagon receptors) in phase 3. Eloralintide works on amylin receptors and is earlier in development. Different mechanisms, different trial stages — cross-trial weight-loss figures are not a head-to-head comparison. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
What users report here
Anonymous accounts are collected on the Retatrutide reports. They are personal stories, often with other compounds in the mix, not evidence of effect.
related peptides:
community guides:
More confessions from the archive
Community Q&A
- Which is stronger, eloralintide or retatrutide?
- No head-to-head trial exists. Comparing averages across separate trials is misleading.
- Are they the same kind of drug?
- No. Retatrutide is incretin/glucagon-based; eloralintide is amylin-based.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.